Department of Pharmaceutical Administration and Economics, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hoan Kiem, Hanoi, Vietnam.
Department of Organization and Drug Administration, Faculty of Pharmacy, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam.
Qual Life Res. 2022 Mar;31(3):733-743. doi: 10.1007/s11136-021-02952-9. Epub 2021 Jul 14.
This study aims to evaluate the quality of life (QoL) of chronic myeloid leukemia (CML) patients prescribed with nilotinib as a second-line therapy and explores the influential factors.
A multicenter retrospective survey was conducted via face-to-face interviews based on the EORTC QLQ-C30 questionnaire. A total of 121 adult CML patients resistant to imatinib and used nilotinib for at least 3 months were enrolled. The influential features were assessed by multiple linear regression models.
Patients had the mean age of 47.49 (SD = 13.67) years, dominated by middle-aged and male groups. The mean scores of functions ranged from 75 to 83, and those of symptoms were from 5 to 28, with the highest of fatigue (28.28), insomnia (22.87), and pain (21.07). The mean global health status/QoL score was 67.70 (SD = 16.80) with considerable financial difficulties (52.34 (SD = 32.15)). Male patients reported higher functional scores and fewer symptoms compared with female patients. All aspects of QoL became worse with increasing age. Besides age and gender, level of education, duration of nilotinib usage, and comorbidities were also significantly influential factors in many QoL domains. A predicted model for expected mean scores of QoL domains was built based on these factors.
The CML patients treated with nilotinib had the above-moderate QoL scores, a light decrease of functional scores, great financial difficulties, and still experienced symptoms. Strategies and more therapeutic considerations to enhance QoL for CML patients targeted toward women, the old, low educational level, and long duration of nilotinib usage, and many comorbidities are needed in the setting.
本研究旨在评估接受尼洛替尼作为二线治疗的慢性髓性白血病（CML）患者的生活质量（QoL），并探讨其影响因素。
采用多中心回顾性调查，通过面对面访谈，基于 EORTC QLQ-C30 问卷进行。共纳入 121 例对伊马替尼耐药、至少使用尼洛替尼 3 个月的成年 CML 患者。采用多元线性回归模型评估影响因素。
患者的平均年龄为 47.49（SD=13.67）岁，以中老年人和男性为主。功能评分均值为 75-83 分，症状评分均值为 5-28 分，其中疲劳（28.28）、失眠（22.87）和疼痛（21.07）得分最高。总体健康状况/生活质量评分的均值为 67.70（SD=16.80），经济困难较大（52.34（SD=32.15））。与女性患者相比，男性患者的功能评分较高，症状较少。随着年龄的增加，QoL 的各个方面都变得更差。除年龄和性别外，教育程度、尼洛替尼使用时间和合并症也是许多 QoL 领域的显著影响因素。根据这些因素建立了 QoL 各领域预期平均得分的预测模型。
接受尼洛替尼治疗的 CML 患者的 QoL 评分处于中上水平，功能评分略有下降，经济困难较大，仍存在症状。在这种情况下，需要针对女性、老年人、低教育程度、尼洛替尼使用时间长和合并症多的 CML 患者制定提高 QoL 的策略和更多治疗考虑。
